Regulation of interferon lambda-1 (IFNL1/IFN-λ1/IL-29) expression in human colon epithelial cells
Introduction
The type III IFNs were first described in 2003 in two independent studies, describing three highly related cytokines known as: IFN-λ1, IFN-λ2 and IFN-λ3 (IL-29, IL-28A and IL-28B, respectively) [1], [2]. These have since been found to have critical roles in coordinating anti-viral and other inflammatory responses. Type III IFNs are members of the IL10-IFN family, which also includes the IL-10-like cytokines (IL-10, IL-19, IL-20, IL-22, IL-24 and IL-26), the type I IFNs (IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω), and the type II IFN, IFN-γ. The gene structures of the IFN-λs (IFNL1, IFNL2, and IFNL3; formerly termed IL29, IL28A, IL28B, respectively) have been reviewed in detail [3], [4] and resemble those of the IL-10-like cytokines rather than those of the intron-less type I IFN genes, cytokines with which type III IFNs share many functional properties. The three IFN-λ proteins are encoded on human chromosome 19q13 and display a high degree of homology (IFN-λ2 and -λ3 being nearly 96% identical at the protein level [1], [3]). Recently, a fourth family member, IFNL4, was described. Interestingly, this gene encodes a functional protein only in primates and is disrupted in individuals of a particular genotype [5].
Expression of the IFNL genes has been found to be responsive to TLR signaling resulting from both viral and bacterial ligands and is most pronounced in plasmacytoid dendridic cells (pDCs) and epithelial cells [3], [4], [6]. Other cell-types, such as monocytes and fibroblasts, also express them [1], [2], [3], [4], [6]. All IFN-λ ligands signal through a single heterodimeric receptor complex consisting of the IL-28Rα signaling chain and the accessory chain IL-10Rβ [1], [3]. While several cell types can be induced to produce the IFN-λ ligands, expression of the type III IFN receptor is restricted to epithelial cells and leukocytes, including pDCs and T cells; therefore IFN-λ ligands are selectively active on these cell types [7], [8], [9], [10], [11], [12], [13], [14], [15], [16]. The primary outcome of type III IFN signaling is similar to that of type I IFNs. pSTAT1 homodimer and pSTAT1/2 heterodimer signal transduction leads to the activation of target-gene promoter GAS and ISRE elements, respectively [1], resulting in the expression of interferon-stimulated genes (ISGs) encoding anti-viral proteins such as 2′5′-oligoadenylate synthetase 1 and 2 (OAS1 and 2), Mx-1 and 2 proteins, and IFN-inducible dsRNA-activated protein kinase [4]. While the outcome of type I and type III IFN expression may appear redundant, differences in receptor distribution confer selectivity of effect. Type III IFN expression and response is most prominent at mucosal surfaces such as in the lungs and gastro-intestinal tract, while type I IFN expression and response is most prominent in liver, spleen and kidneys [14]. This selective receptor expression confers tight regulation of the response to type III IFNs to epithelial cells at mucosal surfaces and to the pDCs that can survey those surfaces, pointing to an important regulatory function for type III IFNs at the interfaces between the body and the outside environment.
Due to functional similarities between the type I and type III IFNs, promoter regulation studies have drawn comparisons between type III and type I IFNs. Initial work focused on proximal control elements contained within the first 600 bp 5′ of the transcription start site (TSS); NF-κB and IRF sites were found to be occupied within the first 300 bases of the IFN-λ1 promoter following Newcastle Disease Virus infection, for example [17]. The effect of NF-κB and IRF on IFNL promoter function was also investigated by Osterlund et al., whose overexpression studies suggested that IFNL1 was regulated by IRF3, while IFNL2 and IFNL3 were more responsive to IRF7 [18]. These authors drew comparison with type I IFN regulation; IFNB is regulated by IRF-3 while IFNA is more dependent on IRF-7 [19], [20], [21]. A more recent study of IFNL1 activation in response to bacteria found that activation was dependent upon distal NF-κB sites at −1137 and −1183 bp of the promoter in monocyte-derived dendritic cells (MDDC) [22], demonstrating that the regulation of IFNL1 can be both stimulation and cell-type specific.
We recently presented the first characterization of IFNL1 transcriptional regulation in human bronchial epithelial cells. We studied both the endogenous gene and luciferase reporter constructs extending to 4 kb 5′ of the transcription start site, and revealed a hitherto undescribed role for ZEB1 as a powerful and selective IFNL1 transcriptional repressor [23]. BLIMP-1 (previously characterized as an IFN-β repressor) was also shown to repress IFNL1. In addition, we further defined roles for NF-κB and IRF; NF-κB c-REL/p52 and c-REL/p65 heterodimers, and IRF1, were activators while the NF-κB-p50 homodimer was repressive. Thus, we demonstrated that while there is overlapping regulation of type I and type III IFNs in these cells, ZEB1 (also known as AREB6 and TCF8 [24]) represents a key point of differential regulation between IFNL1 and the type I IFNs, suggesting possible specific modulation of the type III IFNs.
The type III IFNs show potentially important mucosal epithelia specificity and anti-viral properties within the gastro-intestinal tract. Mice lacking functional receptors for type III IFNs in their intestinal epithelia were impaired in their ability to control oral infection by rotavirus, while mice lacking functional receptors for type I IFN signaling were not. Treatment of mice with IFN-λ repressed rotavirus replication in the gut while type I IFN did not [25]. In addition, using intestinal cell lines and murine and human colonic tissue, IFN-λ1 and IFN-λ2 were demonstrated to be strong inhibitors of HCMV protein expression, thereby causing an increased expression of anti-viral proteins such as Mx-1 and OAS1. This study also demonstrated that increased IFN-λ1 led to induction of the neutrophil chemoattractant IL-8, which further associates type III IFNs with inflammatory responses [26] and confirms an earlier similar observation in human PBMC [8].
Mucosal epithelial cells such as those of the colon not only provide a physical barrier against pathogens such as viruses but also serve as regulators of innate and adaptive immune responses, secreting cytokinesin response to viral infection and so triggering cellular infiltration and polarization of T-cells [3]. Expression and subsequent secretion of IFN-λ1 is thought to be a critical factor in maintaining the epithelial/immune cell interface particularly through its ability to inhibit Th2 polarization [3], [9], [11], [12]. Thus it was of interest for us in this study to determine how IFN-λ1 expression is regulated in colon epithelial cells exposed to viral insult. In the present study we identified the key transcription factors acting on endogenous IFNL1 expression in colon epithelia responding to the viral-mimic poly I:C.
Section snippets
Cell culture and stimulation
The SW480 (CCL-228) and HT-29 (HTB-28) cell lines were purchased from the American Tissue Culture Collection (ATCC; Rockville, MD). Both cell lines were maintained as described by ATCC; SW480 cells were maintained in DMEM (GIBCO, Grand Island, NY) containing 4.5 g/L D-glucose and L-glutamine, while HT-29 cells were maintained in McCoy’s 5A (GIBCO) containing L-glutamine. Both cell lines were grown to 80% confluence then passaged by trypsinization using TrypLETM (GIBCO). For stimulation of
IFN-λ1 is inducible by poly I:C in human colon epithelial cells
Previous studies have shown that the type III IFNs are inducible by viral signaling through TLR3 [6], [17], [18], [28]. Since the intact IFNL1 gene is found in humans and not mice [29], our focus is on this member of the type III IFN family in the colon, although IFNL2 and IFNL3 were also found to be induced, similarly to IFNL1 (data not shown). To ensure that we could properly induce IFNL1 in a model for expression in colon epithelia we used the SW480 and HT-29 cell lines stimulated with poly
Discussion
The type III IFNs are an exciting family of genes that display potent immunological effects [3]. Along with their influence over adaptive immunity [9], [11], [12], [13], the type III IFNs are known to induce potent anti-viral responses as part of innate immunity [1], [2], [3], a function they share with the type I IFNs. Nevertheless, the restricted response to the IFN-λs at epithelial-environment interfaces distinguishes this family from the more widely-expressed type I IFNs [10], [25], [26].
Acknowledgements
This work was supported intramurally by HUMIGEN LLC. All authors are employees of HUMIGEN LLC.
References (46)
- et al.
IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties
Cytokine Growth Factor Rev
(2010) - et al.
IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells
Blood
(2009) - et al.
IL-4 enhances IFN-lambda1 (IL-29) production by plasmacytoid DCs via monocyte secretion of IL-1Ra
Blood
(2010) - et al.
Viral infections activate types I and III interferon genes through a common mechanism
J Biol Chem
(2007) - et al.
Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7
FEBS Lett
(1998) - et al.
Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction
Immunity
(2000) - et al.
The phosphorylation status of nuclear NF-kappa B determines its association with CBP/p300 or HDAC-1
Mol Cell
(2002) - et al.
Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome
Cell
(1995) - et al.
Ordered recruitment of chromatin modifying and general transcription factors to the IFN-beta promoter
Cell
(2000) - et al.
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex
Nat Immunol
(2003)
IL-28, IL-29 and their class II cytokine receptor IL-28R
Nat Immunol
The lambda interferons: guardians of the immune-epithelial interface and the T-helper 2 response
J Interferon Cytokine Res
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
Nat Genet
Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells
Eur J Immunol
Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner
Genes Immun
Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29)
Genes Immun
Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response
Genes Immun
IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo
PLoS Pathog
Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro
Immunology
Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29)
J Leukoc Biol
Temporal and spatial resolution of type I and III interferon responses in vivo
J Virol
Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells
J Immunol
IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes
J Immunol
Cited by (21)
Reducing off-target drug accumulation by exploiting a type-III interferon response
2023, Journal of Controlled ReleaseUnveil the mysterious mask of cytokine-based immunotherapy for melanoma
2017, Cancer LettersCitation Excerpt :IL-29 has been implicated in various immunological responses and displays the similar antiviral, anti-proliferative and immunomodulatory activities that are observed in IFN-α and IFN-β due to the utilization of the same signaling pathway [104,105]. Unlike IFN-α and IFN-β which affect a more broad range of cells, however, IL-29 specifically targets cells of epithelial origin and higher levels of IL-29 are correlated with infections of the GI and respiratory tracts in various reports [109–112]. In addition, IL-29 also displays possible tumor promoting effects in multiple myeloma while exhibiting tumor inhibitory properties in various cancers including melanoma, suggesting its potential in cancer immunotherapy [113].
The role of IL-29 in immunity and cancer
2016, Critical Reviews in Oncology/HematologyCitation Excerpt :IL-29 primarily targets epithelial cells. High IL-29 levels are therefore present during infections of the GI, respiratory tracts, and mucosal regions (He et al., 2010; Sommereyns et al., 2008; Iversen et al., 2010; Swider et al., 2014; Lazear et al., 2015). A study by Witte et al. demonstrated that IL-29 targeted skin cells include keratinocytes and melanocytes, while endothelial cells, subcutaneous adipocytes, and fibroblasts are not targeted (Witte et al., 2009).
Microbial pathogenesis and type III interferons
2016, Cytokine and Growth Factor ReviewsCitation Excerpt :Antiviral signaling downstream of type III IFNs is partially dependent on NF-κB and MAPK signaling activation, which could explain why in human airway epithelial culture type I IFN signaling was the primary contributor to anti-viral signaling in response to RSV [30,36,37]. Recently, transcription factor Med23 was shown to selectively upregulate type III not type I IFN, while type III IFN was selectively downregulated by ZEB1 [38,39]. Therefore, while the type III IFN family is capable of activating the same genes as other IFN families, restricted receptor expression and dependence on other signaling pathways for optimal gene induction limit the influence of type III IFNs on immunity however, once activated the type III IFN family can have a more prolonged role in host defense.
Interferon-λ: Immune Functions at Barrier Surfaces and Beyond
2015, ImmunityCitation Excerpt :A bioinformatic and biochemical analysis of the region upstream of human IFNL1 identified binding sites for the transcription factors ZEB1 and BLIMP-1. Experiments using chromatin immunoprecipitation and gene silencing established that ZEB1 and BLIMP-1 bind the IFNL1 promoter and repress transcription in airway and intestinal epithelial cell lines (Siegel et al., 2011; Swider et al., 2014). ZEB1 activity is specific to IFNL1 and does not regulate IFNB expression.
- 1
HUMIGEN LLC is part of the Genesis Biotechnology Group